Zhang H - Search Results

1

Mutational spectrum and precision oncology for biliary tract carcinoma.

Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H, Wang K, Wang X, Zhao H. Lin J, et al. Among authors: zhang l, zhang h. Theranostics. 2021 Mar 4;11(10):4585-4598. doi: 10.7150/thno.56539. eCollection 2021. Theranostics. 2021. PMID: 33754015 Free PMC article.

2

Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Jiang T, Li X, Wang J, Su C, Han W, Zhao C, Wu F, Gao G, Li W, Chen X, Li J, Zhou F, Zhao J, Cai W, Zhang H, Du B, Zhang J, Ren S, Zhou C, Yu H, Hirsch FR. Jiang T, et al. Among authors: zhang j, zhang h. Theranostics. 2017 Oct 17;7(19):4753-4762. doi: 10.7150/thno.21687. eCollection 2017. Theranostics. 2017. PMID: 29187901 Free PMC article. Clinical Trial.

3

Clinical Outcome and Molecular Analysis of a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Mutation V834L.

Li J, Zhang L, Wu Y, Yang W, Yang Z, Zhang H. Li J, et al. Among authors: zhang l, zhang h. J Thorac Oncol. 2018 Oct;13(10):e189-e191. doi: 10.1016/j.jtho.2018.04.021. Epub 2018 Apr 27. J Thorac Oncol. 2018. PMID: 29705137 Free article. No abstract available.

4

Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma.

He G, Chen Y, Zhu C, Zhou J, Xie X, Fei R, Wei L, Zhao H, Chen H, Zhang H. He G, et al. Among authors: zhang h. Am J Transl Res. 2019 Mar 15;11(3):1428-1445. eCollection 2019. Am J Transl Res. 2019. PMID: 30972172 Free PMC article.

5

Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1.

Peng Y, Zhang L, Zeng T, Liu L, Liu X, Yang Y, Zhang H, Ruan Z. Peng Y, et al. Among authors: zhang l, zhang h. J Thorac Oncol. 2020 Jan;15(1):e4-e8. doi: 10.1016/j.jtho.2019.08.007. J Thorac Oncol. 2020. PMID: 31864557 Free article. No abstract available.

6

Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.

Tang Y, Li Y, Zhang L, Tong G, Ou Z, Wang Z, Zhang H, Qiao G. Tang Y, et al. Among authors: zhang l, zhang h. Thorac Cancer. 2020 Apr;11(4):1094-1098. doi: 10.1111/1759-7714.13361. Epub 2020 Feb 20. Thorac Cancer. 2020. PMID: 32077636 Free PMC article.

7

Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.

Pang X, Qian J, Jin H, Zhang L, Lin L, Wang Y, Lei Y, Zhou Z, Li M, Zhang H. Pang X, et al. Among authors: zhang l, zhang h. J Immunother Cancer. 2020 Jul;8(2):e000463. doi: 10.1136/jitc-2019-000463. J Immunother Cancer. 2020. PMID: 32636238 Free PMC article.

8

Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.

Jiang T, Jiang L, Dong X, Gu K, Pan Y, Shi Q, Zhang G, Wang H, Zhang X, Yang N, Li Y, Xiong J, Yi T, Peng M, Song Y, Fan Y, Cui J, Chen G, Tan W, Zang A, Guo Q, Zhao G, Wang Z, He J, Yao W, Wu X, Chen K, Hu X, Hu C, Yue L, Jiang D, Wang G, Liu J, Yu G, Li J, Zhang H, Wu L, Fang L, Liang D, Zhao Y, Zhao W, Xie W, Ren S, Zhou C. Jiang T, et al. Among authors: zhang g, zhang x, zhang h. Theranostics. 2021 Jan 1;11(1):257-267. doi: 10.7150/thno.51243. eCollection 2021. Theranostics. 2021. PMID: 33391473 Free PMC article.

9

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma.

Yue D, Qian J, Chen Z, Zhang B, Chen P, Zhang L, Li J, Zhang H, Wang C. Yue D, et al. Among authors: zhang l, zhang b, zhang h. J Immunother Cancer. 2021 Feb;9(2):e001967. doi: 10.1136/jitc-2020-001967. J Immunother Cancer. 2021. PMID: 33558279 Free PMC article.

10

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.

Yang X, Hu Y, Yang K, Wang D, Lin J, Long J, Xie F, Mao J, Bian J, Guan M, Pan J, Huo L, Hu K, Yang X, Mao Y, Sang X, Zhang J, Wang X, Zhang H, Zhao H. Yang X, et al. Among authors: zhang j, zhang h. J Immunother Cancer. 2021 May;9(5):e001942. doi: 10.1136/jitc-2020-001942. J Immunother Cancer. 2021. PMID: 33972389 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

119,494 results

Search Page